Персонализированный подход к выбору контрацептива: взвешиваем все за и против

1. FDA Office of Surveillance and Epidemiology. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
2. US Food and Drug Administration. Birth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm299605.h...
3. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349: 1443.
4. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283.
5. ESHRE Capri Workshop Group, Collins J, Crosignani PG. Endometrial bleeding. Hum Reprod Update 2007; 13: 421.
6. Endrikat J, Gerlinger C, Plettig K et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecol Endocrinol 2003; 17: 107.
7. Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol 1996; 174:628.
8. Lawrie TA, Helmerhorst FM, Maitra NK et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011: CD004861.
9. Jacobs HS, Knuth UA, Hull MG, Franks S. Post-"pill" amenorrhoea-cause or coincidence? Br Med  J 1977; 2: 940.
10. Davis AR, Kroll R, Soltes B et al. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril 2008; 89: 1059.
11. Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998; 128: 467.
12. Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981; 305: 612.
13. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study. Lancet 1981; 1: 541.
14. Lidegaard Ø, Løkkegaard E, Jensen A et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257.
15. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989; 298: 165.
16. Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001; 161: 1065.
17. Petitti DB. Hormonal contraceptives and arterial thrombosis – not risk-free but safe enough. N Engl J Med 2012; 366: 2316.
18. Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol 2002; 99: 1100.
19. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348: 498.
20. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348: 505.
21. Heinemann LA, Lewis MA, Thorogood M et al. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from International Study on Oral Contraceptives and Health of Young Women. BMJ 1997; 315: 1502.
22. Petitti DB, Sidney S, Bernstein A et al. Stroke in users of low-dose oral contraceptives. N Engl  J Med 1996; 335: 8.
23. Schwartz SM, Siscovick DS, Longstreth WT Jr et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997; 127: 596.
24. Kemmeren JM, Tanis BC, van den Bosch MA et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33: 1202.
25. Bushnell C, McCullough LD, Awad IA et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 1545.
26. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
27. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
28. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135.
29. de Bastos M, Stegeman BH, Rosendaal FR et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014: CD010813.
30. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335: 651.
31. Harlow SD, Gass M, Hall JE et al. Executive summary of the Stages of Reproductive Aging Workshop+10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97: 1159.
32. Bromberger JT, Schott LL, Kravitz HM et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry 2010; 67: 598.
33. Randolph JFJr, Zheng H, Sowers MR et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011; 96: 746.
34. Randolph JFJr, SowersM, Gold EB et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status.  J Clin Endocrinol Metab 2003; 88: 1516.
35. Van Voorhis BJ, Santoro N, Harlow S et al. The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol 2008; 112: 101.
36. Gold EB, Colvin A, Avis N et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006; 96: 1226.
37. Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstet Gynecol Clin North Am 2011; 38: 519.
38. APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.
39. Rimsza ME. Dysfunctional uterine bleeding. Pediatr Rev 2002; 23: 227.

________________________________________________

1. FDA Office of Surveillance and Epidemiology. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
2. US Food and Drug Administration. Birth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm299605.h...
3. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349: 1443.
4. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283.
5. ESHRE Capri Workshop Group, Collins J, Crosignani PG. Endometrial bleeding. Hum Reprod Update 2007; 13: 421.
6. Endrikat J, Gerlinger C, Plettig K et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecol Endocrinol 2003; 17: 107.
7. Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. Am J Obstet Gynecol 1996; 174:628.
8. Lawrie TA, Helmerhorst FM, Maitra NK et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev 2011: CD004861.
9. Jacobs HS, Knuth UA, Hull MG, Franks S. Post-"pill" amenorrhoea-cause or coincidence? Br Med  J 1977; 2: 940.
10. Davis AR, Kroll R, Soltes B et al. Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive. Fertil Steril 2008; 89: 1059.
11. Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998; 128: 467.
12. Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981; 305: 612.
13. Further analyses of mortality in oral contraceptive users. Royal College of General Practitioners' Oral Contraception Study. Lancet 1981; 1: 541.
14. Lidegaard Ø, Løkkegaard E, Jensen A et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257.
15. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989; 298: 165.
16. Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001; 161: 1065.
17. Petitti DB. Hormonal contraceptives and arterial thrombosis – not risk-free but safe enough. N Engl J Med 2012; 366: 2316.
18. Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol 2002; 99: 1100.
19. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348: 498.
20. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996; 348: 505.
21. Heinemann LA, Lewis MA, Thorogood M et al. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from International Study on Oral Contraceptives and Health of Young Women. BMJ 1997; 315: 1502.
22. Petitti DB, Sidney S, Bernstein A et al. Stroke in users of low-dose oral contraceptives. N Engl  J Med 1996; 335: 8.
23. Schwartz SM, Siscovick DS, Longstreth WT Jr et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997; 127: 596.
24. Kemmeren JM, Tanis BC, van den Bosch MA et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002; 33: 1202.
25. Bushnell C, McCullough LD, Awad IA et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 1545.
26. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
27. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
28. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350: h2135.
29. de Bastos M, Stegeman BH, Rosendaal FR et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014: CD010813.
30. Hannaford PC, Selvaraj S, Elliott AM et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335: 651.
31. Harlow SD, Gass M, Hall JE et al. Executive summary of the Stages of Reproductive Aging Workshop+10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97: 1159.
32. Bromberger JT, Schott LL, Kravitz HM et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry 2010; 67: 598.
33. Randolph JFJr, Zheng H, Sowers MR et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011; 96: 746.
34. Randolph JFJr, SowersM, Gold EB et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status.  J Clin Endocrinol Metab 2003; 88: 1516.
35. Van Voorhis BJ, Santoro N, Harlow S et al. The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause. Obstet Gynecol 2008; 112: 101.
36. Gold EB, Colvin A, Avis N et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health 2006; 96: 1226.
37. Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstet Gynecol Clin North Am 2011; 38: 519.
38. APGO educational series on women's health issues. Clinical management of abnormal uterine bleeding. Association of Professors of Gynecology and Obstetrics, 2006.
39. Rimsza ME. Dysfunctional uterine bleeding. Pediatr Rev 2002; 23: 227.

Ю.Э.Доброхотова, Е.И.Боровкова*

ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*katyanikitina@mail.ru

________________________________________________

Yu.E.Dobrokhotova, E.I.Borovkova*

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, RussianFederation, Moscow, ul. Ostrovitianova, d. 1
*katyanikitina@mail.ru